Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pro-DexFRA:PDXN -5.56%70 EV-to-FCF is 26.41 as of Jul. 16, 2026, which is 73% above its 10-year median of 15.31. GuruFocus rates FRA:PDXN with a GF Score™ of 70/100 and a GF Value™ of €36.60 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 413 Medical Devices & Instruments companies, Pro-Dex ranks worse than 54.72% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pro-Dex's Enterprise Value is €165.85 Mil.
Pro-Dex's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €6.28 Mil. Therefore, Pro-Dex's EV-to-FCF for today is 26.41.
The historical rank and industry rank for Pro-Dex's EV-to-FCF or its related term are showing as below:
FRA:PDXN'
s EV-to-FCF Range Over the Past 10 Years
Min: -395.36 Med: 15.31 Max: 160.43
Current: 25.73
During the past 13 years, the highest EV-to-FCF of Pro-Dex was 160.43. The lowest was -395.36. And the median was 15.31.
FRA:PDXN's EV-to-FCF is ranked worse than 54.72% of 413
companies
in the Medical Devices & Instruments industry
Industry Median: 23.72
vs FRA:PDXN: 25.73
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pro-Dex's share price for today is €51.00.
Pro-Dex's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.107.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Pro-Dex EV-to-FCF Related Terms
Pro-Dex EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Pro-Dex's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PDXN vs KRMD, EMBC, SMTI: EV-to-FCF Comparison
For the Medical Instruments & Supplies subindustry, Pro-Dex's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pro-Dex EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pro-Dex's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Pro-Dex's EV-to-FCF falls into.
Pro-Dex's current Enterprise Value is €165.85 Mil.
Pro-Dex's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pro-Dex (FRA:PDXN) has a EV-to-FCF of 26.41 as of Jul. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pro-Dex and its competitors. This is 73% above median its historical median of 15.31. According to the industry distribution chart, Pro-Dex ranks #226 out of 413 companies in the Medical Devices & Instruments industry, placing it in the top 54.7%.
Is Pro-Dex's EV-to-FCF too high?
Pro-Dex's current EV-to-FCF of 26.41 is 73% above median its 10-year median of 15.31. The Medical Devices & Instruments industry median EV-to-FCF is 23.72. Pro-Dex's value of 26.41 is 11.3% above this industry median. Based on the distribution chart, Pro-Dex ranks #226 out of 413 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Pro-Dex has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pro-Dex's EV-to-FCF compare to KRMD and EMBC?
According to the Medical Devices & Instruments industry distribution chart, Pro-Dex ranks #226 out of 413 companies for EV-to-FCF. This places Pro-Dex in the lower half of its industry. The industry median EV-to-FCF is 23.72. Pro-Dex's value of 26.41 is 11.3% above this benchmark. While the company's 10-year median is 15.31 vs. the industry median of 23.72, Pro-Dex has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.72, based on 413 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pro-Dex's current EV-to-FCF of 26.41 is 11.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pro-Dex and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pro-Dex's current EV-to-FCF is 26.41, which is 73% above median its own 10-year median of 15.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro-Dex stock overvalued right now?
Based on GuruFocus' analysis, Pro-Dex (FRA:PDXN) is currently considered Significantly Overvalued. The stock's GF Value™ is €36.60, compared to a current price of €51.00 — trading 39.3% above its estimated fair value. The current EV-to-FCF is 26.41, which is 73% above median its 10-year median of 15.31 and 11.3% above the Medical Devices & Instruments industry median of 23.72. Pro-Dex's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Pro-Dex (FRA:PDXN), the current EV-to-FCF is 26.41 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pro-Dex (FRA:PDXN) Overvalued in 2026?
Based on GuruFocus' analysis, Pro-Dex stock appears to be overvalued.
The current stock price of €51.00 is trading 39.3% above its estimated GF Value™ of €36.60.
GuruFocus considers Pro-Dex to be Significantly Overvalued.
Key valuation signals for FRA:PDXN:
EV-to-FCF: 26.41 (73% above median its 10-year median of 15.31)
GF Value™: €36.60 vs. price of €51.00 (39.3% above fair value)
Industry Position: 11.3% above the Medical Devices & Instruments median (#226 of 413)
No single metric tells the full story. See the FRA:PDXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.
70GF Score
Get the complete analysis for FRA:PDXN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PDXN has been successfully added to your 
